Peter Lawrinson1, Jan Copeland, Devon Indig. 1. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. plawrinson@unsw.edu.au
Abstract
AIM: To develop a brief, multi-dimensional instrument for routine, on-going treatment outcome monitoring in alcohol and other drug (AOD) services in Australia and examine the underlying psychometric properties. This study focuses on opioid maintenance pharmacotherapy (OMP) services. DESIGN: Researcher-administered test-retest interviews and clinician administered interviews. SETTING: The test-retest interviews took place in two private and two public OMP clinics in Sydney, Australia. The clinician-administered interviews took place in 37 metropolitan, rural and prison OMP services in New South Wales, Australia. PARTICIPANTS: One hundred and sixty current OMP clients for the test-retest interviews and 2004 clients commencing OMP treatment for the clinician-administered interviews. MEASURES: Thirty-two items across the domains of dependence, blood-borne virus exposure risk, drug use, health/psychological functioning and social functioning. FINDINGS: The internal reliability of the brief treatment outcome measure (BTOM) is satisfactory. Retest reliabilities for the scales and drug use scores are good to excellent indicating their consistency with multiple measurements across time and different interviewers and concurrent validation of BTOM scales with analogous scales from similar instruments yielded acceptable agreement. Average completion times of the BTOM were 14.5 min, when administered in a research context and 21 min in a clinical context. CONCLUSIONS: A brief, valid and reliable questionnaire has been developed for monitoring treatment outcome over the range of OMP services. The BTOM contains a core set of outcome measures, which can be easily adapted for integration into routine clinical practice across the range of AOD services.
AIM: To develop a brief, multi-dimensional instrument for routine, on-going treatment outcome monitoring in alcohol and other drug (AOD) services in Australia and examine the underlying psychometric properties. This study focuses on opioid maintenance pharmacotherapy (OMP) services. DESIGN: Researcher-administered test-retest interviews and clinician administered interviews. SETTING: The test-retest interviews took place in two private and two public OMP clinics in Sydney, Australia. The clinician-administered interviews took place in 37 metropolitan, rural and prison OMP services in New South Wales, Australia. PARTICIPANTS: One hundred and sixty current OMP clients for the test-retest interviews and 2004 clients commencing OMP treatment for the clinician-administered interviews. MEASURES: Thirty-two items across the domains of dependence, blood-borne virus exposure risk, drug use, health/psychological functioning and social functioning. FINDINGS: The internal reliability of the brief treatment outcome measure (BTOM) is satisfactory. Retest reliabilities for the scales and drug use scores are good to excellent indicating their consistency with multiple measurements across time and different interviewers and concurrent validation of BTOM scales with analogous scales from similar instruments yielded acceptable agreement. Average completion times of the BTOM were 14.5 min, when administered in a research context and 21 min in a clinical context. CONCLUSIONS: A brief, valid and reliable questionnaire has been developed for monitoring treatment outcome over the range of OMP services. The BTOM contains a core set of outcome measures, which can be easily adapted for integration into routine clinical practice across the range of AOD services.
Authors: Thijs Fassaert; Steve Lauriks; Stef van de Weerd; Jan Theunissen; Martijn Kikkert; Jack Dekker; Marcel Buster; Matty de Wit Journal: Community Ment Health J Date: 2013-12-12
Authors: John S Cacciola; Arthur I Alterman; Dominick Dephilippis; Michelle L Drapkin; Charles Valadez; Natalie C Fala; David Oslin; James R McKay Journal: J Subst Abuse Treat Date: 2012-08-14
Authors: Cameron M Yi; Andrew S Huhn; J Gregory Hobelmann; John Finnerty; Bernadette Solounias; Kelly E Dunn Journal: J Addict Med Date: 2021-10-05 Impact factor: 4.647
Authors: Richard Hallinan; Séverine Crettol; Kingsley Agho; John Attia; Jacques Besson; Marina Croquette-Krokar; Robert Hämmig; Jean-Jacques Déglon; Andrew Byrne; John Ray; Andrew A Somogyi; Chin B Eap Journal: Eur J Clin Pharmacol Date: 2009-07-29 Impact factor: 2.953
Authors: Elizabeth Sullivan; Stephen Ward; Reem Zeki; Sarah Wayland; Juanita Sherwood; Alex Wang; Faye Worner; Sacha Kendall; James Brown; Sungwon Chang Journal: BMJ Open Date: 2019-07-24 Impact factor: 2.692
Authors: Joanne Neale; Silia Vitoratou; Emily Finch; Paul Lennon; Luke Mitcheson; Daria Panebianco; Diana Rose; John Strang; Til Wykes; John Marsden Journal: Drug Alcohol Depend Date: 2016-06-15 Impact factor: 4.492